Site-specifically conjugated anti-HER2 Affibody® molecules as one-step reagents for target expression analyses on cells and xenograft samples

被引:42
作者
Lundberg, Emma
Hoiden-Guthenberg, Ingmarie
Larsson, Barbro
Uhlen, Mathias
Graslund, Torbjorn [1 ]
机构
[1] Royal Inst Technol, Dept Biotechnol, Albanova Univ Ctr, SE-10691 Stockholm, Sweden
[2] Affibody AB, SE-16102 Bromma, Sweden
关键词
ErbB-2; HER2/neu; Affibody molecule; flow cytometry; immunofluorescence; immunoprecipitation;
D O I
10.1016/j.jim.2006.10.013
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Affibody (R) molecules are a class of small and robust affinity proteins that can be generated to interact with a variety of antigens, thus having the potential to provide useful tools for biotechnological research and diagnostic applications. In this study, we have investigated Affibody-based reagents interacting specifically with the tyrosine kinase receptor HER2. A head-to-tail dimeric construct was site-specifically conjugated with different fluorescent and enzymatic groups resulting in reagents that were used for detection and quantification. The amount of cell surface expressed HER2 oil eleven (11) well characterized cell lines was quantified relative to each other by flow cytometry and shown to correlate well with results from parallel analyses of HER2 mRNA levels measured by real-time PCR. Further, immunofluorescence I microscopy studies of the cell lines and immunohistochemical analyses of cryosections of HER2 expressing SKOV-3 xenografts showed strong staining of the plasma membrane of tumor cells with little background staining. Full-length HER2 protein Could also be efficiently recovered from a cell extract by an immunoprecipitation procedure, using an Affibody ligand-based resin. These novel non-IgG derived reagents could be used to detect and quantify HER2 expression. By adapting the methods for use with Affibody molecules binding to other cell surface receptors, it is anticipated that also these receptors can be detected and quantified in a similar manner. (c) 2006 Elsevier B.V All rights reserved.
引用
收藏
页码:53 / 63
页数:11
相关论文
共 34 条
[1]   Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies [J].
Andersson, M ;
Rönnmark, J ;
Areström, I ;
Nygren, PÅ ;
Ahlborg, N .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 283 (1-2) :225-234
[2]   Engineering novel binding proteins from nonimmunoglobulin domains [J].
Binz, HK ;
Amstutz, P ;
Plückthun, A .
NATURE BIOTECHNOLOGY, 2005, 23 (10) :1257-1268
[3]  
BORG A, 1990, CANCER RES, V50, P4332
[4]   Directed evolution of ATP binding proteins from a zinc finger domain by using mRNA display [J].
Cho, GS ;
Szostak, JW .
CHEMISTRY & BIOLOGY, 2006, 13 (02) :139-147
[5]  
Eklund M, 2004, J BIOTECHNOL, V109, P277, DOI 10.1016/j.jbiotec.2004.01.008
[6]   Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein [J].
Engfeldt, T ;
Renberg, B ;
Brumer, H ;
Nygren, PÅ ;
Karlström, AE .
CHEMBIOCHEM, 2005, 6 (06) :1043-1050
[7]   A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products [J].
Gräslund, S ;
Eklund, M ;
Falk, R ;
Uhlén, M ;
Nygren, PÅ ;
Ståhl, S .
JOURNAL OF BIOTECHNOLOGY, 2002, 99 (01) :41-50
[8]   Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization [J].
Hammock, L ;
Lewis, M ;
Phillips, C ;
Cohen, C .
HUMAN PATHOLOGY, 2003, 34 (10) :1043-1047
[9]   An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein [J].
Hansson, M ;
Ringdahl, J ;
Robert, A ;
Power, U ;
Goetsch, L ;
Nguyen, TN ;
Uhlén, M ;
Ståhl, S ;
Nygren, PÅ .
IMMUNOTECHNOLOGY, 1999, 4 (3-4) :237-252
[10]   Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization:: a technical review with interpretive guidelines [J].
Hicks, DG ;
Tubbs, RR .
HUMAN PATHOLOGY, 2005, 36 (03) :250-261